Arlene Weintraub

Arlene Weintraub
Arlene Weintraub
Contributing Writer

Arlene Weintraub has over 15 years of experience writing about health care, pharmaceuticals and biotechnology. Her freelance pieces have been published in the New York Times, US News & World Report, Technology Review, Scientific American, USA Today,, FierceMarkets and other media outlets. She was previously a senior health writer for BusinessWeek, covering both the science and business of health. She also worked as an editor for, covering the biotech industry, as well as technology, life sciences and clean technology companies. She has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the antiaging industry, Selling the Fountain of Youth, was published by Basic Books in 2010.

Stories by Arlene Weintraub

black and white cow

Could a cow virus help fight multiple myeloma?

One of the most active research endeavors in immuno-oncology involves engineering human viruses into weapons that can fight cancer. Now a group of scientists at the University of Parma in Italy is looking to another source of potentially potent cancer-killing viruses: cows.
A close image of a blue eye

Salk scientists use new gene editing approach to restore sight in rats

The gene-editing approach called CRISPR-Cas9 has been grabbing headlines for its potential to address diseases ranging from cancer to sickle cell disease—but scientists at the Salk Institute may have found a way to improve upon the technology. And they’ve shown it could hold promise for restoring some sight in adults who are blind.

Scientists successfully grow working minilungs from stem cells

When scientists at the University of Michigan attempted to transplant their stem cell-derived miniature lungs into mice, they failed, because the minilungs lacked the maturity and structure needed to be able to facilitate breathing. So the biologists teamed up with biomedical engineers to develop a solution to the problem.

FDA grants humanitarian use for Miltenyi's stem cell transplant device

Miltenyi Biotec said today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, related donors. The device, called the CliniMACS CD34 Reagent System, is designed to lower the risk of graft-versus-host disease (GVHD), which is a common complication of this type of transplant.